


The following listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1. - 10. (Cancelled)

11. (Previously Presented): A compound of formula I



wherein

Y₁ means a hydrogen atom, a hydroxyl group, an alkanoyloxy group with 1 to 12 C atoms or an aroyloxy group,

Y₂ means a hydrogen atom or an alkanoyl group with 1 to 12 C atoms or an aroyl group,

R₁ and R₂ each mean a hydrogen atom or together an exocyclic methylene group,

R₃ and R₄, independently of one another, mean a hydrogen atom, a chlorine or fluorine atom, an alkyl group with 1 to 4 carbon atoms, or together form a methylene group, or together with quaternary carbon atom 20 form a 3- to 7-membered, saturated or unsaturated carbocyclic ring,

Q means a straight-chain or branched carbon unit with up to 10 carbon atoms, which at any position can have hydroxyl groups, in α- or β-position, which in turn can be etherified or esterified, keto groups, amino groups or halogen atoms,

R₅ and R₆ together with carbon atom 25 mean a 3- to 7-membered, saturated or unsaturated carbocyclic ring,

Z means a five- or six-membered carbocyclic ring which can be saturated, unsaturated or aromatic, and which can be substituted by one or more alkyl chains, which can be straight-

chain or branched, saturated or unsaturated, and optionally interrupted by oxa, thia, aza, sulfoxide or sulfo groups or substituted by hydroxy groups or halogen atoms, wherein if Z is phenyl, R₅ and R₆ together with carbon atom 25 form a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl ring.

12. (Previously Presented): A compound according to claim 11, wherein R₅ and R₆ together with carbon atom C-25 means a cyclopropyl ring.

13. (Previously Presented): A compound according to claim 11, wherein Q is hydroxymethyl or carbonylmethyl group.

14. (Previously Presented): A compound according to claim 11, wherein the compound antagonizes the action of calcitriol in HL 60 cells.

15. (Previously Presented): A compound according to claim 11, wherein Y₁ is acetyloxy, propionyloxy, butyryloxy or benzoyloxy.

16. (Previously Presented): A compound according to claim 11, wherein Y₂ is acetyl, propionyl, butyryl or benzoyl.

17. (Previously Presented): A compound according to claim 11, wherein R₃ is H and R₄ is methyl.

18. (Previously Presented): A compound according to claim 11, wherein R₃ is methyl and R₄ is H.

19. (Previously Presented): A compound according to claim 11, wherein R₃ is F and R₄ is methyl.

20. (Previously Presented): A compound according to claim 11, wherein R₃ is methyl and R₄ is F.

21. (Previously Presented): A compound according to claim 11, wherein R₃ and R₄ together form a methylene group or together with tertiary carbon atom 20 form a cyclopropyl group.
22. (Previously Presented): A compound according to claim 11, wherein Q is an unsubstituted, unbranched alkylene having 1-3 carbon atoms.
23. (Previously Presented): A compound according to claim 11, wherein Q is hydroxymethylene in which the hydroxy group is in the α or β position.
24. (Previously Presented): A compound according to claim 11, wherein Q is -CH(OH)-CH₂- or -CH(OH)-CH₂-CH₂- in which, in each case, the hydroxy group is in the α or β position.
25. (Previously Presented): A compound according to claim 11, wherein R₅ and R₆ together with carbon atom C-25 form a cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl group.
26. (Previously Presented): A composition comprising at least one compound according to claim 11 and a pharmaceutically compatible vehicle.
27. (Currently Amended): A method of treating a patient suffering from ~~for~~ hyperproliferative diseases of the skin, tumor diseases and precancerous stages, auto-immune diseases, rejection reactions in the case of autologous, allogenic or xenogenic transplants, ~~AIDS~~, atopic skin conditions, secondary hyperparathyroidism, renal osteodystrophia, senile and postmenopausal osteoporosis, or diabetes mellitus type II, ~~and/or degenerative diseases of the peripheral and central nervous system~~ comprising administering to said patient a compound ~~composition~~ according to claim 11.
28. (Currently Amended): A method according to claim 27, wherein said patient is suffering from psoriasis, acne, ichthyosis, tumors of the intestines, carcinomas of the breast, lung tumors, prostate carcinomas, leukemias, T-cell lymphomas, actinic keratoses, cervix dysplasias, multiple sclerosis, diabetes mellitus type I, myasthenia gravis, lupus

erythematosis, AIDS, secondary hyperparathyroidism, renal osteodystrophia, senile osteoporosis, postmenopausal osteoporosis, diabetes mellitus type II, ~~Alzheimer's disease~~ and/or amyotrophic lateral sclerosis.


29. (Currently Amended): A method of treating a patient suffering from ~~for~~ hypercalcemias, granulomatous diseases, paraneoplastic hypercalcemias, hypercalcemias in hyperparathyroidism, hirsutism, arteriosclerosis, and/or inflammatory diseases comprising administering to said patient a compound ~~composition~~ according to claim 11, wherein the compound antagonizes the action of calcitriol in HL 60 cells.

30. (Currently Amended): A method according to claim 29, wherein said patient is suffering from hypervitaminosis D, ~~intoxication with calcitriol or its analogues~~, sarcoidosis, tuberculosis, osteolytic metastases, tumors with increased synthesis of parathormone-related peptides, hypercalcemias in hyperparathyroidism, hirsutism, arteriosclerosis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, and/or granulomatous diseases.

31. (Previously Presented): A method according to claim 27, wherein said compound is administered to said patient in an amount of 0.1 $\mu\text{g/day}$ - 1000 $\mu\text{g/day}$.

32. (Previously Presented): A method according to claim 29, wherein said compound is administered to said patient in an amount of 0.1 $\mu\text{g/day}$ - 1000 $\mu\text{g/day}$.

33. (Previously Presented): A process for the production of a compound according to claim 11, said process comprising:
providing a compound of general formula II



ALBRE-30-D3

wherein

Y'₁ means a hydrogen atom or a protected hydroxy group and

Y'₂ means a hydroxy protective group,

R₁ and R₂ each mean a hydrogen atom or together an exocyclic methylene group,

R₃ and R₄, independently of one another, mean a hydrogen atom, a chlorine or fluorine atom, an alkyl group with 1 to 4 carbon atoms, or together form a methylene group, or together with quaternary carbon atom 20 form a 3- to 7-membered, saturated or unsaturated carbocyclic ring,

Q means a straight-chain or branched carbon unit with up to 10 carbon atoms, which at any position can have hydroxyl groups, in α- or β-position, which in turn can be etherified or esterified, keto groups, amino groups or halogen atoms,

R₅ and R₆ together with carbon atom 25 mean a 3- to 7-membered, saturated or unsaturated carbocyclic ring, and

Z' means a five- or six-membered carbocyclic ring which can be saturated, unsaturated or aromatic, and which can be substituted by one or more alkyl chains, which can be straight-chain or branched, saturated or unsaturated, and optionally interrupted by oxa, thia, aza, sulfoxide or sulfo groups or substituted by hydroxy groups or halogen atoms, wherein if Z' is phenyl, R₅ and R₆ together with carbon atom 25 form a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl ring; and

reacting the compound by simultaneous or successive cleavage of the hydroxy protective groups and optionally by partial or complete esterification(s) or etherification(s) of free hydroxy groups.

34. (Previously Presented): A compound selected from:

(5Z,7E,22E)-(1S,3R,24R)-25-phenyl-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24S)-25-phenyl-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24R)-25-(4-methylphenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24S)-25-(4-methylphenyl)-26,27-cyclo-9,10-secocholesta-
5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24R)-25-(4-ethylphenyl)-26,27-cyclo-9,10-secocholesta-
5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24S)-25-(4-ethylphenyl)-26,27-cyclo-9,10-secocholesta-
5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24R)-25-(4-propylphenyl)-26,27-cyclo-9,10-secocholesta-
5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24S)-25-(4-propylphenyl)-26,27-cyclo-9,10-secocholesta-
5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24R)-25-(4-butylphenyl)-26,27-cyclo-9,10-secocholesta-
5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24S)-25-(4-butylphenyl)-26,27-cyclo-9,10-secocholesta-
5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24R)-25-(4-pentylphenyl)-26,27-cyclo-9,10-secocholesta-
5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24S)-25-(4-pentylphenyl)-26,27-cyclo-9,10-secocholesta-
5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24R)-25-(3-methylphenyl)-26,27-cyclo-9,10-secocholesta-
5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24S)-25-(3-methylphenyl)-26,27-cyclo-9,10-secocholesta-
5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24R)-25-(3-ethylphenyl)-26,27-cyclo-9,10-secocholesta-
5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24S)-25-(3-ethylphenyl)-26,27-cyclo-9,10-secocholesta-
5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24R)-25-(3-propylphenyl)-26,27-cyclo-9,10-secocholesta-
5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24S)-25-(3-propylphenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24R)-25-(3-butylphenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24S)-25-(3-butylphenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24R)-25-(3-pentylphenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24S)-25-(3-pentylphenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24R)-25-[4-(1-methylethyl)phenyl]-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol

(5Z,7E,22E)-(1S,3R,24S)-25-[4-(1-methylethyl)phenyl]-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24R)-25-[3-(1-methylethyl)phenyl]-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol, and

(5Z,7E,22E)-(1S,3R,24S)-25-[3-(1-methylethyl)phenyl]-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol.

35. (Currently Amended): A method of treating a patient suffering from a hyperproliferative disease of the skin selected from psoriasis, pityriasis subia pilasis, acne, and ichthyosis, comprising administering to said patient a compound composition according to claim 11.

36. (Currently Amended): A method of treating a patient suffering from a tumor disease or a precancerous stage of a tumor, selected from tumors of the intestines, carcinomas of the breast, lung tumors, prostate carcinomas, leukemias, T-cell lymphomas, melanomas, Batazell Larzin, squamous carcinoma, actinic keratoses, cervix dysplasias, and metastasizing tumors, said method comprising administering to said patient a compound composition according to claim 11.

37. (Currently Amended): A method of treating a patient suffering from eczema or a disease of the atopic Formon series, comprising administering to said patient a compound ~~composition~~ according to claim 11.

38. (Currently Amended): A method of treating a patient suffering from an auto-immune diseases selected from multiple sclerosis, diabetes mellitus type I, myasthenia gravis, lupus erythematosus, scleroderma, and bullous skin diseases, comprising administering to said patient a compound ~~composition~~ according to claim 11.

39. (Currently Amended): A method of treating a patient suffering further rejection reactions resulting from an autologous, allogeneic or xenogeneic transplant, comprising administering to said patient a compound ~~composition~~ according to claim 11.

40. (Currently Amended): A method of treating a patient suffering from diabetes mellitus type II by increasing the insulin secretion, comprising administering to said patient a compound ~~composition~~ according to claim 11.

41. (Currently Amended): A method of treating a patient suffering from senile osteoporosis, postmenopausal osteoporosis, or steroid-induced osteoporosis, comprising administering to said patient a compound ~~composition~~ according to claim 11.

42. (Currently Amended): A method of accelerating healing of arthroplasties in a patient comprising administering to said patient a compound ~~composition~~ according to claim 11.